New targets for inhibitors of HIV-1 replication

Nature Reviews Molecular Cell Biology

Volumn 1, Issue 1, 2000, Pages 40-49

  Moore, John P ^a   Stevenson, Mario ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RECEPTOR;

BINDING SITE; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MEMBRANE FUSION; METABOLISM; PHYSIOLOGY; REVIEW; VIRUS DNA CELL DNA INTERACTION; VIRUS REPLICATION;

ANTI-HIV AGENTS; BINDING SITES; HIV-1; HUMANS; MEMBRANE FUSION; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECEPTORS, HIV; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 0034304841     PISSN: 14710072     EISSN: None     Source Type: Journal    
DOI: 10.1038/35036060     Document Type: Review

References (105)

1. Palella, F. J. Jr et al. Declining morbidity and mortality, among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853-860 (1998).
2. Lucas, G. M., Chaisson, R. E. & Moore, R. D. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 131, 81-87 (1999).
3. Yerly, S. et al. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354, 729-733 (1999).
4. Furtado, M. R. et al. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. W. Engl. J. Med. 340, 1614-1622 (1999).
5. Van Damme, L. & Rosenberg, Z. F. Microbicides and barrier methods in HIV prevention. AIDS 13, S85-S92 (1999).
6. Mondor, I., Ugolini, S. & Sattentau, Q. J. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4-independent and gp120 dependent and requires cell surface heparans. J. Virol. 72, 3623-3634 (1998).
7. Moulard, M. et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74, 1948-1960 (2000).
8. Geijtenbeek, T. B. H. et al. DC SIGN, a dendritic cell specific HIV-1-binding protein that enhances transinfection of T cells. Cell 100, 575-585 (2000).
9. Liao, Z., Roos, J. W. & Hildreth, J. E. K. Increased infectivity of HIV type 1 particles bound to cell surface and solid-phase ICAM-1 and VCAM-1 through acquired adhesion molecules LFA-1 and VLA-4. AIDS Res. Hum. Retroviruses 16, 355-366 (2000).
10. Esser, M. T. et al. Cyanovirin-N binds to gp120 to interfere with CD4 dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J. Virol. 73, 4360-4371 (1999).
11. Delezay, O., Hammache, D., Fantini, J. & Yahi, N. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids. Biochemistry 35, 15663-15671 (1996).
12. Kwong, P. D. et al. Structure of an HIV gp120 envelope glycoprotein complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659 (1998).
13. Zhang, J. L. et al. The bis-azo compound FP 21399 inhibits HIV-1 replication by preventing viral entry. Virology 244, 530-541 (1998).
14. Bugelski, P. J., Ellens, H., Hart, T. K. & Kirsh, R. L. Soluble CD4 and dextran sulphate mediate release of gp120 from HIV-1: Implications for clinical trials. J. Acq. Immun. Def. Synd. 4, 923-924 (1991).
15. Cabrera, C. et al. Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4. AIDS Res. Hum. Retroviruses 15, 1535-1543 (1999).
16. Jacobson, J. M. et al. Single-dose safety, pharmacology and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis. 182, 326-329 (2000).
17. Zhang, W. et al. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. Biochemistry 38, 9405-9416 (1999).
18. Vita, C. et al. Rational engineering of a miniprotein that reproduces the core of the.CD4 site interacting with HIV-1 envelope glycoprotein. Prac. Natl Acad. Sci. USA 96, 13091-13096 (1999).
19. Reimann, K. A. et al. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res. Hum. Retroviruses 13, 933-943 (1997).
20. Berger, E. A. HIV entry and tropism: the chemokine receptor connection. AIDS 11, S3-S16 (1997).
21. Michael, N. L. et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5Δ 32. J. Virol. 72, 6040-6047 (1998).
22. Zhang, Y.-J. & Moore, J. P. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1? J. Virol. 73, 3443-3448 (1999).
23. Glushakova, S. et al. Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo. J. Clin. Invest. 104, R7-R11 (1999).
24. Berger, E. A. et al. A new classification for HIV-1. Nature 391, 240 (1998).
25. Veazey, R. S. et al. Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J. Virol. 74, 57-64 (2000).
26. + T cell decline. Proc. Natl Acad. Sci. USA 97, 1269-1274 (2000).
27. Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion of the CKR5 structural allele. Science 273, 1856-1862 (1996).
28. Wu, L. et al. CCR5 levels and expression pattern correlate with infectability by macrophage tropic HIV-1, in vitro. J. Exp. Med. 185, 1681-1691 (1997).
29. Zou, Y. R., Kottmann, A. H., Kuroda, M., Taniuchi, I. & Littman, D. R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393, 595-599 (1998).
30. Datema, R. et al. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob. Agents Chemother. 40, 750-754 (1996).
31. - T cells. Science 270, 1811-1815 (1995).
32. Bleul, C. C. et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382, 829-833 (1996).
33. Obertin, E. et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line adapted HIV-1. Nature 382, 833-835 (1996).
34. Simmons, G. et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276, 276-279 (1997).
35. Heveker, N. et al. Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides. Curr. Biol. 8, 369-376 (1998).
36. Amara, A. et al. HIV coreceptor downregulation as antiviral principle: SDF-1α-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J. Exp. Med. 186, 139-146 (1997).
37. Mack, M. et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 187, 1215-1224 (1998).
38. Trkola, A. et al. Genetic subtype independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J. Virol. 72, 396-404 (1998).
39. + T cells: Role of signal transduction. Proc. NatlAcad. Sci. USA 95, 11880-11885 (1998).
40. Marechal, V., Arenzana-Seisdedos, F., Heard, J.-M. & Schwartz, O. Opposite effects of SDF-1 on human immunodeficiency virus type 1 replication? J. Virol. 73, 3608-3615 (1999).
41. Trkola, A. et al. The CC chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosoaminoglycans, and also activates a signal transduction pathway that enhances viral infectivity. J. Virol. 73, 6370-6379 (1999).
42. Mosier, D. E. et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 73, 3544-3550 (1999).
43. Endres, M. J. et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 87, 745-756 (1996).
44. Olson, W. C. et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC chemokine activity by monoclonal antibodies to CCR5. J. Virol. 73, 4145-4155 (1999).
45. Schols, D. et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186, 1383-1388 (1997).
46. Murakami, T. et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med. 186, 1389-1393 (1997).
47. Doranz, B. J. et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 186, 1395-1400 (1997).
48. Donzella, G. A. et al. AMD3100, a small molecule inhibitor of HPV-1 entry via the CXCR4 co-receptor. Nature Med. 4, 72-77 (1998).
49. Arakaki, R. et al. T134, a small-molecule CXCR4 inhibitor, has no cross drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J. Virol. 73, 1719-1723 (1999).
50. Sakaida, H. et al. T-tropic human immunodeficiency virus type 1 (HIV-1) derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection. J. Virol. 72, 9763-9770 (1998).
51. Baba, M. et al. A small molecule nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl Acad. Sci. USA 96, 5698-5703 (1999).
52. Howard, O. M. Z. et al. Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: A candidate for chemotherapeutic and microbicidal application. J. Med. Chem. 41, 2184-2193 (1998).
53. Wild, C., Oas, T., McDanal, C., Bolognesi, D. & Matthews, T. A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition. Proc. Natl Acad. Sci. USA 89, 10537-10541 (1992).
54. Jiang, S., Lin, K., Strick, N. & Neurath, A. R. HIV-1 inhibition by a peptide. Nature 365, 113 (1993).
55. Jones, P. L., Korte, T. & Blumenthal, R. Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J. Biol. Chem. 273, 404-409 (1998).
56. Kilby, J. M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 4, 1302-1307 (1998).
57. Ferrer, M. et al. Selection of gp41-mediated HIV-1 cell entry inhibition from biased combinational libraries of non-natural binding elements. Nature Struct. Biol. 6, 953-959 (1999).
58. Eckert, D. M., Malashkevich, V. N., Hong, L. H., Carr, P. A. & Kim, P. S. Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled coil pocket. Cell 99, 103-115 (1999).
59. Labrosse, B., Treboute, C. & Alizon, M. Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 env-mediated fusion depends on the sequence and accessibility of the gp41 loop region. J. Virol. 74, 2142-2150 (2000).
60. Wilson, C. et al. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J. Virol. 64, 3240-3248 (1990).
61. Pritsker, M., Jones, P., Blumenthal, R. & Shai, Y. A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV 1 envelope glycoprotein-mediated cell fusion. Proc. Natl Acad. Sci. USA 95, 7287-7292 (1998).
62. Rimsky, L. T., Shugars, D. C. & Matthews, T. J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72, 986-993 (1998).
63. De Vreese, K. et al. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Virol. 70, 689-696 (1996).
64. Schols, D., Esté, J. A., Cabrera, C. & De Clercq, E. T-cell-line tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1α contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J. Virol. 72, 4032-4037 (1998).
65. Esté, J. A. et al. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to X5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J. Virol. 73, 5577-5585 (1999).
66. Maeda, Y., Foda, M., Matsushita, S. & Harada, S. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. J. Virol. 74, 1787-1793 (2000).
67. Franke, E. K., Yuan, H. E. H. & Luban, J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372, 359-362 (1994).
68. Thali, M. et al. Functional association of cyclophilin A with HIV-1 virions. Nature 372, 363-365 (1994).
69. Braaten, D. et al. Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that gag encodes functional target of cyclophilin A. J. Virol. 70, 5170-5176 (1996).
70. Montaner, J. S., Montessori, V. Harrigan, R., O'Shaughnessy, M. & Hogg, R. Antiretroviral therapy: 'the state of the art'. Biomed. Phamacother. 53, 63-72 (1999).
71. Gerondelis, P. et al. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end-and DNA 3′-end-directed RNase H activities. J. Virol. 73, 5803-5813 (1999).
72. Darlix, J. L., Lapadat-Tapolsky, M., de Rocquigny, H. & Roques, B. P. First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses. J. Mol. Biol. 254, 523-537 (1995).
73. Tummino, P. J. et al. The in vitro ejection of zinc from human immunodeficiency virus (HIV) type 1 nucleocapsid protein by disulfide benzamides with cellular anti-HIV activity. Proc. Natl Acad. Sci. USA 93, 969-973 (1996).
74. Rice, W. G. et al. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 270, 1194-1197 (1995).
75. Turpin, J. A. et al. Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers. J. Med. Chem. 42, 67-86 (1999).
76. Tanchou, V. et al. Role of the N-terminal zinc finger of human immunodeficiency virus type 1 nucleocapsid protein in virus structure and replication. J. Virol. 72, 4442-4447 (1998).
77. Carteau, S., Gorelick, R. J. & Bushman, F. D. Coupled integration of human immunodeficiency virus type 1 cDNA ends by purified integrase in vitro: stimulation by the viral nucleocapsid protein. J. Virol. 73, 6670-6679 (1999).
78. Berthoux, L., Pechoux, C. & Darlix, J. L. Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication. J. Virol. 73, 10000-10009 (1999).
79. Zack, J. A. et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213-222 (1990).
80. Stevenson, M., Stanwick, T. L. Dempsey, M. P. & Lamonica, C. A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9, 1551-1560 (1990).
81. Kinoshita, S., Chen, B. K., Kaneshima, H. & Nolan, G. P. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 95, 595-604 (1998).
82. Flanagan, W. M., Corthesy, B., Bram, R. J. & Crabtree, G. R. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporine A. Nature 352, 803-807 (1991).
83. Zennou, V. et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101, 173-185 (2000).
84. Charneau, P. et al. HIV-1 reverse transcription. A termination step at the center of the genome. J. Mol. Biol. 241, 651-662 (1994).
85. Bukrinsky, M. I. et al. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc. Natl Acad. Sci. USA 90, 6125-6129 (1993).
86. Hansen, M. S., Carteau, S., Hoffmann, C., Li, L. & Bushman, F. Retroviral cDNA integration: mechanism, applications and inhibition. Genet. Eng. 20, 41-61 (1998).
87. Wiskerchen, M. & Muesing, M. A. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J. Virol. 69, 376-386 (1995).
88. Hazuda, D. et al. Equivalent inhibition of half-site and full-site retroviral strand transfer reactions by structurally diverse compounds. J. Virol. 71, 807-811 (1997).
89. Neamati, N. et al. Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. J. Med. Chem. 41, 3202-3209 (1998).
90. Hazuda, D. J. et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287, 646-650 (2000).
91. Gallay, P., Hope,T., Chin, D. & Trono, D. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc. Natl Acad. Sci. USA 94, 9825-9830 (1997).
92. Pluymers, W., Cherepanov, P., Schols, D., De Clercq, E. & Debyser, Z. Nuclear localization of human immunodeficiency virus type 1 integrase expressed as a fusion protein with green fluorescent protein. Virology 258, 327-332 (1999).
93. Stevenson, M. HIV nuclear import: What's all the flap? Nature Med. 6, 9-10 (2000).
94. Rausch, J. W., Sathyanaryana, B. K., Bona, M. K. & Le Grice, S. F. Probing contacts between the ribonuclease H domain of HIV-1 reverse transcriptase and nucleic acid by site specific photocrosslinking. J. Biol. Chem. 3, 16015-16022 (2000).
95. Simon, J. H., Gaddis, N. C., Fouchier, R. A. & Malim, M. H. Evidence for a newly discovered cellular anti-HIV phenotype. Nature Med. 4, 1397-1400 (1998).
96. Madani, N. & Kabat, D. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72, 10251-10255 (1998).
97. Labrosse, B. et al. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J. Virol. 72, 6381-6388 (1998).
98. Murakami, T. et al. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J. Virol. 73, 7489-7496 (1999).
99. Dragic, T. et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl Acad. Sci. USA 97, 5639-5644 (2000).
100. Tarasova, N. I., Rice, W. G. & Michejda, C. J. Inhibition of G-protein coupled receptor functions by disruption of transmembrane domain interactions. J. Biol. Chem. 274, 34911-34915 (1999).
101. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J. & Wiley, D. C. Atomic structure of the ectodomain from gp41. Nature 387, 426-430 (1997).
102. Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273 (1997).
103. Caffrey, M. et al. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J. 17, 4572-4584 (1998).
104. Farzan, M. et al. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96, 667-676 (1999).
105. Moulard, M. et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74, 1948-1960 (2000).